Literature DB >> 34223564

Instrumental variable approach for estimating a causal hazard ratio: application to the effect of postmastectomy radiotherapy on breast cancer patients.

Fan Yang1, Jing Cheng2, Dezheng Huo3.   

Abstract

The use of postmastectomy radiotherapy (PMRT) on women with AJCC (American Joint Committee on Cancer) pT1-2pN1 breast cancer is controversial in practice. Huo et al. (2015) found that PMRT was associated with longer survival among a high-risk subgroup of AJCC pT1-2pN1 patients using a Cox model on data from the National Cancer Database. To address unmeasured confounding in this observational study, we consider the variation among facilities in the use of PMRT as an instrumental variable (IV). Recently, there has been widespread use of the two-stage residual inclusion (2SRI) method offered by Terza et al. (2008) for nonlinear models, and 2SRI has been the method of choice for analyzing proportional hazards model using IV in clinical studies. However, the causal parameter using 2SRI is only identified under a homogeneity assumption that goes beyond the standard assumptions of IV, and Wan et al. (2015) demonstrated that under standard IV assumptions, 2SRI could fail to consistently estimate the causal hazard ratio for compliers. In this paper, following Yu et al. (2015), we apply a model-based IV approach (Imbens and Rubin, 1997; Hirano et al., 2000) which allows consistent estimation of the causal hazard ratio for survival outcomes with a proportional hazards model specification under standard IV assumptions while flexibly incorporating the restrictions imposed by IV assumptions. Simulation studies show that when there is unmeasured confounding, both 2SRI and the standard Cox regression could provide biased estimates of the causal hazard ratio among compliers, while this model-based IV approach provides consistent estimates. We apply this IV method to the breast cancer study and our IV analysis did not find strong evidence to support the benefit of PMRT on survival among the targeted patients. In addition, we develop sensitivity analysis approaches to assess the sensitivity of causal conclusions to violations of the exclusion restrictions assumption for IV.

Entities:  

Keywords:  Instrumental variable; Proportional hazards model; Sensitivity analysis

Year:  2019        PMID: 34223564      PMCID: PMC8247118          DOI: 10.1353/obs.2019.0008

Source DB:  PubMed          Journal:  Obs Stud


  38 in total

1.  Causal proportional hazards models and time-constant exposure in randomized clinical trials.

Authors:  T Loeys; E Goetghebeur; A Vandebosch
Journal:  Lifetime Data Anal       Date:  2005-12       Impact factor: 1.588

2.  Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable.

Authors:  M Alan Brookhart; Philip S Wang; Daniel H Solomon; Sebastian Schneeweiss
Journal:  Epidemiology       Date:  2006-05       Impact factor: 4.822

3.  Instrumental variable additive hazards models.

Authors:  Jialiang Li; Jason Fine; Alan Brookhart
Journal:  Biometrics       Date:  2014-10-08       Impact factor: 2.571

4.  Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.

Authors:  M Overgaard; M B Jensen; J Overgaard; P S Hansen; C Rose; M Andersson; C Kamby; M Kjaer; C C Gadeberg; B B Rasmussen; M Blichert-Toft; H T Mouridsen
Journal:  Lancet       Date:  1999-05-15       Impact factor: 79.321

5.  Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group.

Authors:  A Recht; R Gray; N E Davidson; B L Fowble; L J Solin; F J Cummings; G Falkson; H C Falkson; S G Taylor; D C Tormey
Journal:  J Clin Oncol       Date:  1999-06       Impact factor: 44.544

6.  Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation.

Authors:  A Katz; E A Strom; T A Buchholz; H D Thames; C D Smith; A Jhingran; G Hortobagyi; A U Buzdar; R Theriault; S E Singletary; M D McNeese
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

7.  Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.

Authors:  M Overgaard; P S Hansen; J Overgaard; C Rose; M Andersson; F Bach; M Kjaer; C C Gadeberg; H T Mouridsen; M B Jensen; K Zedeler
Journal:  N Engl J Med       Date:  1997-10-02       Impact factor: 91.245

8.  Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer.

Authors:  Hung-Jui Tan; Edward C Norton; Zaojun Ye; Khaled S Hafez; John L Gore; David C Miller
Journal:  JAMA       Date:  2012-04-18       Impact factor: 56.272

9.  Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data.

Authors:  Jack Hadley; K Robin Yabroff; Michael J Barrett; David F Penson; Christopher S Saigal; Arnold L Potosky
Journal:  J Natl Cancer Inst       Date:  2010-10-13       Impact factor: 13.506

10.  Using an instrumental variable to test for unmeasured confounding.

Authors:  Zijian Guo; Jing Cheng; Scott A Lorch; Dylan S Small
Journal:  Stat Med       Date:  2014-06-15       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.